Business Context and Reporting Period
Cadrenal Therapeutics, Inc. filed a Form 8-K dated February 12, 2024, reporting events beginning February 6, 2024. The company is an emerging growth pharmaceutical company with common stock trading on Nasdaq under the symbol CVKD.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance figures.
The reported employment arrangement provides for a $405,000 annual base salary for Jeffrey Cole, a discretionary bonus of up to 40% of base salary, and a grant of 150,000 stock options.
Material Changes
- Cadrenal entered into an offer letter with Jeffrey Cole on February 6, 2024, and subsequently entered into an employment agreement effective February 8, 2024.
- The employment agreement supersedes the offer letter and appoints Mr. Cole as Chief Operating Officer.
- Mr. Cole had previously served as a consultant to the company beginning in November 2023.
Compensation, Outlook, and Risks
- Mr. Cole is eligible for a discretionary annual bonus of up to 40% of base salary based on objectives determined by the board’s Compensation Committee.
- If terminated without cause, he is entitled to 12 months of continued base salary, the full target cash bonus for the fiscal year in which termination occurs, and accelerated vesting of outstanding equity awards.
- The company is required to grant 150,000 options under its 2022 Successor Equity Incentive Plan on or before March 14, 2024. The options vest 25% after one year, with the remainder vesting pro rata over 36 months.
- The agreement includes confidentiality obligations. The filing does not provide broader financial guidance or an updated business outlook.
Important Facts to Verify
- Confirm the final execution and terms of the employment agreement and the related exhibits filed with the Form 8-K.
- Verify the issuance date, exercise price, and final vesting terms of the 150,000 stock options.
- Assess the potential cash cost of salary, bonus eligibility, severance, and accelerated equity vesting.
- Review subsequent filings for any changes in Mr. Cole’s employment, compensation, or option grant.